Global AI Signs Enterprise Contract with One of the World’s Largest Pharmaceutical Companies to Automate Compliance Operations

Rhea-AI Summary

Global AI (OTC: GLAI) announced on January 29, 2026 a signed contract with one of the world’s largest pharmaceutical and life sciences companies to deploy its enterprise-grade Agentic AI Platform. The agreement covers automation of regulatory monitoring, compliance reporting, and internal HR operations.

The platform is described as providing full auditability, traceability, and governance across reporting lifecycles to meet enterprise and regulatory standards across multiple jurisdictions, positioning Global AI for broader enterprise adoption.

News Market Reaction

+6.00%

1 alert

+6.00% News Effect

On the day this news was published, GLAI gained 6.00%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Expands presence in highly regulated industries with AI-driven solutions supporting mission-critical regulatory and HR workflows

New York, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Global AI Inc. (OTC: GLAI), a leader in enterprise artificial intelligence (AI), agentic products and solutions, today announced that it has signed a contract with one of the world’s largest pharmaceutical and life sciences companies to automate and govern multiple compliance-critical and data-intensive business processes.

Under the agreement, Global AI will deploy its enterprise-grade Agentic AI Platform to support regulatory monitoring, compliance reporting, and internal human resources operations—areas that demand the highest levels of accuracy, traceability, and auditability. The contract further validates Global AI’s ability to deliver AI-driven automation solutions within large-scale, highly regulated enterprise environments.

The platform’s compliance automation capabilities provide full auditability and governance across the entire reporting lifecycle and are purpose-built to meet enterprise and regulatory standards required by global pharmaceutical organizations operating across multiple jurisdictions.

Darko Horvat, Chairman and CEO of Global AI, commented, “Deploying our agentic AI products within the pharmaceutical industry and complex, compliance-driven environments demonstrates enterprise-scale capability and builds lasting credibility. This provides a foundation for broader adoption of our enterprise AI product suite across processes and business units as organizations increasingly adopt agentic AI.”

About Global AI Inc.

Global AI is a leader in artificial intelligence (AI) agentic products and solutions. Its enterprise grade Agentic AI platform enables organizations to design, deploy, and scale AI workflows with governance and compliance built in. With deep expertise across industries and mission-critical environments, Global AI delivers secure, high-performance AI products that enhance decision-making, accelerate transformation, and create measurable shareholder value.

For more information, please visit www.global.ai.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited, statements regarding the expected timing, scope, performance, benefits, and potential expansion of the Company’s agentic AI platform deployment, the anticipated value of customer engagements, and the Company’s future operations and business prospects. Terms and phrases such as “anticipate,” “believes,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” and other similar terms and phrases, as well as the use of the future tense are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on current beliefs, expectations and assumptions regarding the future of the business of the Company, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to a number of risks and uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control, including the risks described in our registration statements and annual reports under the heading "Risk Factors" as filed with the Securities and Exchange Commission. Actual results and financial condition may differ materially from those indicated in the forward-looking statements due to various factors, including, but not limited to: the customer’s ability to terminate or modify the engagement; delays or challenges in implementation or integration of the Company’s technology; the customer’s acceptance and continued use of the Company’s platform; changes in project scope or timing; regulatory, compliance, data governance, or cybersecurity requirements; competitive pressures; and general market and economic conditions. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements in this press release speak only as of the date hereof. Unless otherwise required by law, we undertake no obligation to publicly update or revise these forward-looking statements, whether because of new information, future events or otherwise.

Contact:
Crescendo Communications, LLC
Email: ir@global.ai
Phone: 212-671-1020

FAQ

What contract did Global AI (GLAI) announce on January 29, 2026?

Global AI announced a contract to deploy its Agentic AI Platform for a major pharmaceutical company. According to the company, the deal covers regulatory monitoring, compliance reporting, and internal HR automation across multiple jurisdictions to ensure auditability and governance.

How will Global AI's Agentic AI Platform support compliance for the pharmaceutical customer?

The platform will automate regulatory monitoring and compliance reporting with full auditability and governance. According to the company, it is purpose-built for traceability across the reporting lifecycle to meet enterprise and regulatory standards in highly regulated environments.

What parts of HR will Global AI (GLAI) automate for the pharmaceutical client?

Global AI will support internal human resources operations that are data-intensive and compliance-critical. According to the company, automation will focus on processes requiring high accuracy, traceability, and auditability to align HR workflows with regulatory demands.

Does the January 29, 2026 announcement state the contract value or timeline for GLAI?

The announcement does not disclose contract value or specific timelines for deployment. According to the company, the agreement is focused on deploying the Agentic AI Platform to address regulatory and HR workflows across multiple jurisdictions.

What does the contract mean for Global AI's (GLAI) enterprise credibility and growth?

The company says the contract validates its enterprise-scale capabilities within highly regulated industries and builds credibility. According to the company, this engagement could serve as a foundation for broader adoption of its enterprise AI product suite across processes and business units.